The CHORUS study
The CHORUS trial is the first of its kind globally to explore treatment for fibrotic hypersensitivity pneumonitis (FHP). It will provide crucial evidence that could reshape how we deliver care.
Help us make a difference - take part, spread the word, change lives.
What is fibrotic hypersensitivity pneumonitis (FHP)?
Fibrotic hypersensitivity pneumonitis (FHP) is a chronic condition affecting the lungs, causing inflammation and scarring. People living with the disease experience symptoms such as difficulty breathing, weight loss, and a hacking cough that gradually gets worse over time. It is thought to affect 11 in 100,000 people, and there are around 2000 cases diagnosed in the UK each year.
What is involved?
We aim to find out whether a commonly prescribed steroid (prednisolone) is an effective treatment for FHP.
Who can take part?
We are looking for people who:
Have been recently diagnosed with fibrotic hypersensitivity pneumonitis (FHP)
Have not yet started treatment
You do not need to travel to Devon to take part. Contact your care team to learn more!
How can I sign up?
To learn more about the trial, speak with your care team or get in touch with us via email: chorus@exeter.ac.uk
Who is running the study?
The study is led by the Royal Devon University Healthcare NHS Foundation Trust in collaboration with the University of Exeter and the NIHR, delivered by the NIHR Exeter Biomedical Research Centre, Exeter Clinical Trials Unit, and the University of Exeter’s Clinical and Biomedical Sciences department.